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Abstract: During hemocompatibility testing, activation products
may reach plateau values which can result in less distinction
between hemocompatible and hemo-incompatible materials. Of
concern is an underestimation of the blood activation caused by
the biomaterial of interest, which may result in a false assess-
ment of hemocompatibility. To elucidate the optimal incubation
time for in vitro hemocompatibility testing, we used the Haemo-
bile circulation model with human whole blood. Blood from
healthy volunteers was in vitro incubated under pulsatile ﬂow
with physiological wall shear stress conditions at 37C for 30, 60,
120, or 240 min. Test loops containing low-density polyethylene
and polydimethylsiloxane served as low and high reference
materials, that is, hemocompatible and hemo-incompatible
biomaterials, respectively. In addition, empty loops served as a
negative reference. Thrombogenicity, platelet function, inﬂa-
mmatory response, coagulation, and hemolysis between refer-
ences and incubation times were compared. We found that
thrombogenicity and platelet function were signiﬁcantly affected
by both the duration of incubation and the type of material. In
particular, thrombogenicity and platelet function assessments
were affected by incubation time. We found that an exposure
time of 60 min was sufﬁcient, and for almost all variables an
optimal incubation time to discriminate between the low and
high reference material. © 2019 The Authors. journal Of Biomedical
Materials Research Part B: Applied Biomaterials Published By Wiley Peri-
odicals, Inc. J Biomed Mater Res B Part B: Appl Biomater 107B:2335–
2342, 2019.
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INTRODUCTION
The lack of standardized methods for hemocompatibility test-
ing constitutes a major problem for the preclinical evaluation
of blood contacting medical devices. Direct contact of bioma-
terials with blood results in the activation of platelets, white
blood cells, the coagulation cascade, the complement system,
and can lead to hemolysis.1,2 Activation of these biological sys-
tems can occur throughout the entire cardiovascular system
and can result in the formation of thrombi and (micro)embo-
lisms which in turn can lead to life-threatening conditions.
The current ISO 10993-Part 4 standard for testing hemo-
compatibility states that “blood or plasma should ﬁrst be
exposed to the material or device under standardized condi-
tions including time, temperature, and ﬂow rate”; however,
appropriate exposure times are not elaborated.3 Literature
shows that blood exposure times during hemocompatibility
testing vary from 15 min to 5 h and is contradictory about
the optimum exposure time.1,4–7
Biomaterials can result in rapid blood activation, adsorp-
tion of proteins, and the activation of platelets. The activation
of platelets can occur in <0.2 s, after which other platelets can
be activated as well and start adhering.2,8 The activation of
the coagulation cascade is somewhat slower and can take up
to several minutes. Material-mediated or mechanically medi-
ated hemolysis take longer exposure times to allow relevant
results. This is clearly described by Henkelman et al., who
reported that medical steel induced 188% more hemolysis
after 24 h of incubation when compared to 4 h of incubation.
Furthermore, they showed that 24 h of incubation resulted in
better distinction between their negative and positive controls
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as compared to 4 h of incubation.9 To obtain an overall
impression of hemocompatibility, the exposure time
for testing must be chosen so that activation of the different
biological systems can be measured and that reference mate-
rials can be discriminated from each other.
To elucidate the optimal incubation time for in vitro
hemocompatibility testing by means of the Haemobile
model,10 we analyzed thrombogenicity, platelet function,
inﬂammatory response, coagulation, and hemolysis of human
whole blood which had been incubated in vitro under pulsa-
tile ﬂow with physiological wall shear stress conditions at
37C for 30, 60, 120, or 240 min. Low-density polyethylene
(LDPE) and polydimethylsiloxane (PDMS) are well known ref-
erence materials used during hemocompatibility testing2,11,12
and, in our study, served as low and high activating reference
materials, that is, hemocompatible and hemo-incompatible
biomaterials, respectively. In addition, empty test loops served
as a negative reference and represented the background acti-
vation of the model. Incubation times with the greatest dis-
tinction between low and high references were identiﬁed.
MATERIALS AND METHODS
Blood collection
Fresh human blood was gently collected in a syringe (Omniﬁx
Solo, B. Braun, Melsungen, Germany) by venipuncture with a
19 G butterﬂy needle from nine apparently healthy adult vol-
unteers (age range: 23–26, male/female: 4/5) who received
no medication within 2 weeks prior to blood withdrawal.
Anticoagulation was achieved with a clinical dose of heparin
(1.5 IU/mL, Leo Pharmaceutical Products BV, Weesp, The
Netherlands).
In vitro incubation
In vitro incubations were performed at 37C using the Haemo-
bile (HaemoScan BV, Groningen, The Netherlands)10 with an
angle of 180 , a clockwise angular velocity of 720/s, an anti-
clockwise angular velocity of 360/s, and no delay between
motions (Figure 1). Test loops consisted of polyvinyl chloride
tubing (180 Clear PVC Tubing USP class VI, Nalgene, New York,
NY) with an internal diameter of 3 mm, were ﬁtted with a
hemocompatible unidirectional check valve (HaemoScan BV,
FIGURE 1. (a) Three-dimensional model of the Haemobile. The black arrows indicate the back and forth movement of the round plateau carrying
the stacked test loops. The test loops have a radius of 72.5 mm. The blue components represent the unidirectional check valves. (b) The angle of
the round plateau in time, with the Haemobile programmed to the following settings: angle of rotation = 180; clockwise angular velocity = 720/s;
anticlockwise angular velocity = 360/s; angular acceleration/deceleration = 3600/s2 (ﬁxed setting). (c) Ensemble average of the measured ﬂow
(solid blue line) and typical coronary blood ﬂow (dashed red line). (d) Calculated shear stress across the internal diameter of the test loop in time.
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Groningen, The Netherlands), and contained ~3 mL of blood.
These conditions resulted in a unidirectional and pulsatile ﬂow
with an average ﬂow of 19.4 mL/min and an average wall shear
stress of 0.50 Pa (5 dyne/cm2). The average ﬂow and (wall)
shear stress was calculated based on Doppler measurements of
ﬂuid velocity.10 The calculated values were close to typical aver-
age wall shear stresses observed in coronary arteries [0.68 Pa
(6.8 dyne/cm2)].10,13
LDPE ﬂat sheets (Goodfellow Cambridge Ltd., Hunting-
don, England) and PDMS ﬂat sheets (RX Silicone, ERIKS BV,
Alkmaar, The Netherlands) served as low and high refer-
ences, respectively. Reference materials were cut into
5 × 0.3 cm pieces (3 cm2) and cleaned by sonication in 70%
ethanol for 15 min. After sonication, reference materials
were air-dried and placed into the test loops, resulting in
blood/surface ratios of ~1 mL/cm2. In addition, empty loops
were used as negative reference. In vitro incubations were
performed in duplicate for exposure times of 30, 60, 120, or
240 min, resulting in 24 test loops per donor.
Heparinized whole blood was transferred from the syringe
to the test loop by connecting the syringe to the hemocompati-
ble unidirectional check valve and by gently ﬁlling the test loop
and displacing all remaining air in the test loop. As described
previously, storage of whole blood affects key determinants of
hemocompatibility within 4 h of blood collection.1,3,4,11 There-
fore, the time between blood collection and initiation of in vitro
incubations was kept to a minimum, never exceeding 30min.
After incubation, reference materials were gently rinsed
three times with 50 mM Tris-buffered saline, pH 7.6 using
tweezers and dipping in three 100 mL beakers (to prevent
washing away any of the adhered components), photographed,
cut to pieces of 10 × 3 mm (60 mm2), transferred to polysty-
rene tubes (Greiner Bio-One GmbH, Frickenhausen, Germany)
and stored at 2C–8C until further use. Incubated blood was
collected in polystyrene tubes (Greiner Bio-One GmbH) and
immediately split in two aliquots, of which one aliquot was
centrifuged at 79g for 5 min to obtain platelet-rich plasma
(PRP) and one aliquot was anticoagulated with 10% (v/v)
ethylenediaminetetraacetic acid (EDTA) to a ﬁnal concentra-
tion of 5 mM (preventing any further blood activation).
Thrombogenicity
Thrombi adhered to LDPE and PDMS were visualized by means
of macroscopy and scanning electron microscopy. For scanning
electron microscopy, pieces of reference materials were ﬁxated
with 2% (v/v) glutaraldehyde/0.1 M cacodylate buffer and
dehydrated with an ethanol series and solutions containing tet-
ramethylsilane.14 Materials were sputter-coated with gold/pal-
ladium (SC7620 Mini Sputter Coater, Quorum Technologies
Ltd., UK) before visualization with a tabletop scanning electron
microscope (Phenom-World BV, Eindhoven, The Netherlands).
In addition to the visualization of adhered thrombi, platelet
adhesion was also quantiﬁed as an indicator for thrombogenicity.
Platelet adhesion was quantiﬁed based on the presence of acid
phosphatase15 in platelet granules using exposure of ~1 cm2 of
material to a citrate buffer containing 4-nitrophenylphosphatase
and Triton X-100 (acid phosphatase substrate). The optical den-
sity was measured before and after addition of sodium hydroxide
(PowerWave 200, Bio-Tek Instruments, Inc., Winooski, VT).
Counted platelets in PRP (cell counter Medonic CA 530, Sweden)
served as a standard curve, whereby the amount of adhered
platelets could be determined.
Fibrin binding was quantiﬁed on 1 cm2 of material by
means of an enzyme immunoassay (EIA), based on a biotin-
conjugated mouse anti ﬁbrin bèta chain IgG antibody
(American Diagnostica GmbH, Pfungstadt, Germany) fol-
lowed by horseradish peroxidase (HRP)-conjugated strepta-
vidin (Thermo Fisher Scientiﬁc Inc., Waltham, MA) and a
citrate–phosphate buffer containing o-phenylenediamine and
hydrogen peroxide (OPD substrate).
Platelet function
Cell count was performed (Medonic CA 530) on whole blood
containing 5 mM EDTA, and counted cells were corrected for
the EDTA dilution. The remaining EDTA containing whole
blood was centrifuged at 13,400g for 1 min, and the platelet
poor plasma (PPP) was stored at −80C until further analysis.
In addition to quantifying platelet adhesion as an indicator
for thrombogenicity, the remaining capacity of platelets to
adhere to collagen was used to assess platelet function. The
capacity of platelets to adhere to collagen was analyzed in
collagen-coated microtiter plates as we described previously.1
Brieﬂy, platelet adhesion was achieved by incubating PRP in a
collagen-coated microplate, unattached platelets were
removed by washing with phosphate-buffered saline, pH 7.4,
and adhered platelets were analyzed using acid phosphatase
substrate similar to the quantiﬁcation of platelet adhesion,
and the percentage of adhered platelets was calculated.
P-selectin (CD62P), stored in α-granules of platelets, is rapidly
expressed on the surface of activated platelets, functioning as an
adhesion receptor for white blood cells to mediate adhesion to
endothelial cells.16 P-selectin can be used as an indicator for plate-
let activation. Surface-bound P-selectin expression was quantiﬁed
bymeans of an EIA, based on a mouse anti-human P-selectin anti-
body (clone 9E1, R&D Systems, Inc., Minneapolis, MN) followed
by an HRP-conjugated rabbit anti mouse IgG antibody (Sigma-
Aldrich Co. LLC., St. Louis, MO) and OPD substrate.
In addition to expression of P-selectin on platelet surfaces,
platelet activation leads to activation of the arachidonic acid
synthesis pathway to produce thromboxane A2 (TXA2) which
is highly unstable and rapidly converted to thromboxane B2
(TXB2).1 Thromboxane B2 in PPP was analyzed by means of
an EIA (Cayman Chemical Company, Ann Arbor, MI), based on
the competition between labeled TXB2 and sample TXB2.
Inﬂammatory response, coagulation, and hemolysis
White blood cells were counted (Medonic CA 530) and elastase
in PPP was analyzed as indicators for white blood cell activa-
tion. Elastase was measured by means of an enzyme-linked
immunosorbent assay (ELISA) based on a capture antibody
against human elastase and a labeled antibody against alpha
1 anti-trypsin (Afﬁnity Biologicals Inc., Ancaster, Canada).
Complement complex C5b-9 in PPP was analyzed as an
indicator for complement activation by means of ELISA based
on a mouse anti human C5b-9 capture antibody (DAKO,
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: APPLIED BIOMATERIALS | OCT 2019 VOL 107B, ISSUE 7 2337
ORIGINAL RESEARCH REPORT
Glostrup, Denmark) and a goat anti C5 detection antibody
(Quidel, San Diego, CA).
Thrombin–antithrombin III (TAT III) complex in PPP was
analyzed to determine thrombin formation, as an indicator
for coagulation activity. Thrombin–antithrombin III complex
was analyzed by means of ELISA, using a capture antibody
against human thrombin and a labeled antibody against anti-
thrombin III (Cedarlane Laboratories Ltd., Hornby, Canada).
Free hemoglobin in PPP was used as an indicator for
hemolysis and was measured as described by Harboe.17 Per-
centage of hemolysis was determined by comparison with a
100% hemolysis sample.
Statistical analysis
Normally distributed variables were reported as mean + one
standard deviation. Baseline concentrations of elastase and
complement complex C5b-9 showed great interindividual
differences. These variations were eliminated for elastase
and complement complex C5b-9 by normalizing the data to a
percentage of the baseline (% baseline). Paired samples
t test was used for all parameters to assess any signiﬁcant
differences between the baseline and 30, 60, 120, or
240 min of incubation. Independent samples t test was used
for all parameters to assess differences between reference
materials. All tests performed to test the (null-) hypothesis
of no difference were two-sided. A p value <0.05 was consid-
ered statistically signiﬁcant. Statistical analyses were per-
formed with SPSS version 16.0 for Windows (SPSS Inc.,
Chicago, IL).
FIGURE 2. Macroscopic image of low-density polyethylene (LDPE) and
polydimethylsiloxane (PDMS) ﬂat sheets after in vitro incubation under
pulsatile ﬂow with physiological wall shear stress conditions with
human whole blood at 37C for 1 h. LDPE barely showing thrombus for-
mation; PDMS clearly showing vast red-thrombus formation.
FIGURE 3. Scanning electron microscopy images of low-density polyethylene (LDPE) and polydimethylsiloxane (PDMS) surfaces before and after
in vitro incubation under pulsatile ﬂow with physiological wall shear stress conditions with human whole blood at 37C for 1 h. (a, b) 375× and
1500× magniﬁcation of LDPE before incubation, respectively. A clean, smooth surface is visible. (c, d) 420× and 1500× magniﬁcation of PDMS
before incubation, respectively. A clean, rough surface is visible. (e, f) 375× and 6000× magniﬁcation of LDPE after incubation, respectively. An
almost clean surface, showing only few adhered platelets is visible. (g, h) 385× and 1500× magniﬁcation of PDMS after incubation, respectively.
The bare polymer surface is almost completely covered by vast thrombus layers, mostly consisting of ﬁbrin and red blood cells.
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RESULTS
Thrombogenicity
Following incubation, visual inspection of the reference
materials already revealed large differences, where LDPE
barely showed thrombus formation and PDMS showed vast
red-thrombus deposition (Figure 2). Electron microscopy of
LDPE mainly revealed separate adhered platelets [Figure 3
(e,f)], while PDMS revealed vast thrombus deposition cover-
ing the entire surface. The thrombi clearly consisted of ﬁbrin,
red blood cells, and platelets [Figure 3(g,h)]. The extent of
thrombus formation on LDPE and PDMS did not seem to
change over time.
Platelet adhesion on LDPE reached a plateau value after
30 min, while on PDMS, it plateaued after 60 min [Figure 4(a)].
The largest difference in platelet adhesion between the refer-
ence materials was observed after 60 min (p ≤ 0.001).
Fibrin binding on LDPE reached a plateau value after
30 min, while on PDMS, it plateaued after 120 min [Figure 4
(b)]. The largest difference in ﬁbrin binding between the
reference materials was observed after 240 min
(p ≤ 0.001).
Platelet function
Mean platelet volume did not change over time or after
exposure to LDPE or PDMS. The number of circulating plate-
lets decreased over time and the largest difference between
the reference materials was observed after 60 min [Figure 5
(a), p = 0.020]. Platelet–collagen adhesion did not change
after exposure to LDPE or PDMS and no clear changes were
observed over time [Figure 5(b)].
During the measured timeframe (0–240 min), surface-
bound P-selectin expression continued to increase after
exposure to LDPE, while PDMS seemed to reach a plateau
value after 60 min [Figure 5(c)]. The largest difference in
surface-bound P-selectin expression between the reference
materials was observed after 60 min (p = 0.023).
Thromboxane B2 release in plasma increased during
incubation, and at most time points, PDMS resulted in signiﬁ-
cantly higher TXB2 concentrations than LDPE and/or the
negative reference [Figure 5(d)]. The largest difference
between LDPE and PDMS was observed after 60 min
(p = 0.012).
Inﬂammatory response, coagulation, and hemolysis
The number of circulating white blood cells did not change
over time or after exposure to LDPE or PDMS. Elastase
release and complement complex C5b-9 formation in plasma
increased over time [Figure 6(a,b)]. There were, however, no
differences between the reference materials.
Similar to the inﬂammatory markers, TAT III complex for-
mation in plasma increased over time. However, there was no
difference between the reference materials [Figure 6(c)].
Free hemoglobin in plasma increased over time, and
again there was no difference between the reference mate-
rials [Figure 6(d)].
DISCUSSION
The aim of this study was to elucidate the optimal incubation
time for in vitro hemocompatibility testing by means of the
Haemobile model. We found that an exposure time of
60 min was sufﬁcient and for most variables an optimal
incubation time to discriminate between the low and high
reference materials. Another important observation was that
the activation markers measured in plasma were not as
effective in discriminating the reference materials from each
other or from the negative reference as the surface-bound
markers, which resulted in very clear differences.
Improper hemocompatibility assessments may result in
unjustly use of blood contacting medical devices that can
lead to extensive inﬂammation and hemolysis, or even a
direct risk for life-threatening conditions as a result of the
formation of blood clots, thrombi, and/or (micro)embo-
lisms.18 Although the thrombogenicity of medical devices
may be attenuated by the administration of platelet inhibi-
tors and/or anticoagulants, higher doses are needed for
FIGURE 4. (a) Platelet adhesion and (b) ﬁbrin binding on low-density
polyethylene (LDPE) and polydimethylsiloxane (PDMS) after in vitro
incubation under pulsatile ﬂow with physiological wall shear stress
conditions with human whole blood at 37C for various incubation
times. **p < 0.05 between indicated references, using an independent
samples t test.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: APPLIED BIOMATERIALS | OCT 2019 VOL 107B, ISSUE 7 2339
ORIGINAL RESEARCH REPORT
FIGURE 5. (a) Whole blood platelet count, (b) platelet adhesion to colla-
gen, (c) surface-bound P-selectin expression, and (d) thromboxane B2
release in plasma after in vitro incubation under pulsatile ﬂow with
physiological wall shear stress conditions with human whole blood at
37C for various incubation times using empty loops (Empty) as nega-
tive reference, low-density polyethylene (LDPE) as low reference, and
polydimethylsiloxane (PDMS) as high reference. *p < 0.05 compared
with the baseline (0 min), using a paired samples t test. **p < 0.05
between indicated references, using an independent samples t test.
FIGURE 6. (a) Elastase release in plasma, (b) complement complex C5b-9
formation in plasma, (c) thrombin–antithrombin III complex formation in
plasma, and (d) free hemoglobin in plasma after in vitro incubation under
pulsatile ﬂow with physiological wall shear stress conditions with human
whole blood at 37C for various incubation times using empty loops
(Empty) as negative reference, low-density polyethylene (LDPE) as low ref-
erence, and polydimethylsiloxane (PDMS) as high reference. *p < 0.05
comparedwith the baseline (0min), using a paired samples t test. **p < 0.05
between indicated references, using an independent samples t test.
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hemo-incompatible medical devices as compared to more
hemocompatible medical devices.19
The exposure time during in vitro testing has been
debated for a long time. Some suggest that the incubation
time should last for many hours, when implants or long-
contact duration devices are involved. However, most
reports show a beneﬁt of shorter exposure times. Seyfert
et al. already suggested that the exposure time of a biomate-
rial to blood should be between 15 and 240 min.4 Braune
et al. stated that the total test duration should not exceed
4 h to ensure an appropriate function of blood cells and
blood plasma proteins.11 Furthermore, Hiebl et al. concluded
that if hemocompatibility tests are focused on the coagula-
tion parameters prothrombin time and ﬁbrinogen, a test
period of 30 min is advantageous to a prolonged test period
of 90 min.7
Our ﬁndings indicate that the optimal incubation time for
in vitro hemocompatibility assessments is 60 min for quanti-
ﬁcation of platelet adhesion, counting of platelets in whole
blood, quantiﬁcation of surface-bound P-selectin expression,
and measurement of TXB2 release in plasma, and 240 min
for quantiﬁcation of ﬁbrin binding. As quantiﬁcation of ﬁbrin
binding also resulted in very clear differences after 60 min
of incubation, our ﬁndings advocate an exposure time of
60 min for in vitro hemocompatibility assessments when
incubating under pulsatile ﬂow with physiological wall shear
stress conditions.
However, this study has several limitations. First, the
results obtained with the Haemobile model may not be
generalized to other models, as other models may incorpo-
rate an air bubble in the test loop, do not use pulsatile
ﬂow, or do not describe the shear stress proﬁle at all. All
in vitro models have activation due to the tubing of the
test loop. Therefore, it is important to minimize that back-
ground noise by using a hemocompatible tubing, such as
USP class VI medical grade PVC. Second, the optimal incu-
bation time found in this study was based on hemocom-
patibility testing of polymers; by changing the
characteristics of the test samples (e.g., when testing
metals instead of polymers, or when testing polymers with
different surface roughness), the optimal incubation time
may be different due to the more hemo-incompatible
nature of metals as compared to polymers. Third, we used
test loops containing ~3 mL of blood and samples of
3 cm2, resulting in blood/surface ratios of ~1 mL/cm2;
altering the volume-to-surface ratio can have an inﬂuence
on the rate of formation of blood activation products,
changing the time until these activation products are
exhausted, possibly changing the distinction between dif-
ferent biomaterials. Fourth, the incubation time of this
study was based on blood which was anticoagulated with
a clinical dose of heparin (1.5 IU/mL); by administrating a
different concentration of heparin or a different anticoagu-
lant (e.g., citrate), the optimal incubation time may change
due to the altered coagulation activity. And ﬁnally, only
one pulsatile waveform shape and shear stress level was
evaluated in this study. This means that for different pul-
satile waveform shapes and corresponding shear stress
levels (these may vary within different arteries), the opti-
mal exposure time may be different.
Although we followed the recommendations of the cur-
rent ISO 10993-Part 4,3 not all activation markers measured
in plasma were inﬂuenced by the type of biomaterial
after exposure to blood. This is in agreement with previous
reports.7,9,20,21 However, decreasing the blood/surface ratio
(e.g., using greater surface areas per ml) may result in
greater distinction between different biomaterials, and thus
signiﬁcant changes in plasma activation markers. For com-
plement activation, coagulation activity, white blood cell acti-
vation, and hemolysis in plasma, no clear differences were
observed between reference materials. Even more disturb-
ing, complement complex C5b-9 in plasma after exposure to
PDMS was lower when compared to LDPE and empty test
loops. This suggests that complement complex C5b-9 was
either bound by PDMS and/or that the formation of comple-
ment complex C5b-9 in plasma was inhibited. Hamad et al.
have shown that certain complement factors (C1q, C4, C3,
and C9) can bind to the surface of activated platelets.22 This
might explain that soluble complement complex C5b-9 in
plasma exposed to PDMS was lower as compared to LDPE
and empty test loops, as PDMS showed extensive adhesion
of activated platelets.
CONCLUSION
This study was set out to determine the effect of exposure
time on the distinction between low and high reference
materials during hemocompatibility testing by means of the
Haemobile model. We observed that an exposure time of
60 min was sufﬁcient, and for most variables an optimal
incubation time to discriminate between the low and high
reference material. In particular, thrombogenicity deter-
mined by deposition of thrombotic components on the mate-
rial surface and platelet function assessments were affected
by incubation time. Especially for these variables, it is impor-
tant to use the optimal incubation time. As our ﬁndings are
in agreement with suggested incubation periods based on
other models,4,7,11 we endorse that in vitro incubations
for hemocompatibility assessments which use circulation
models with human whole blood at 37C should last for
60 min.
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